Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

GYRE THERAPEUTICS, INC. Director's Dealing 2014

Oct 21, 2014

32556_dirs_2014-10-21_57a5e6a7-b9c6-448b-b686-6e1b0735028d.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TARGACEPT INC (TRGT)
CIK: 0001124105
Period of Report: 2014-10-17

Reporting Person: Musso Alan A (SVP, Fin+Admin, CFO & Treas)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2014-10-17 Common Stock A 55000 Acquired 57799 Direct

Footnotes

F1: This restricted stock award vests in two equal, annual installments beginning on December 31, 2015 and becomes vested in full on December 31, 2016.